Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With MS

This cohort study investigates the humoral response to 2 SARS-CoV-2 messenger RNA vaccines in patients with multiple sclerosis treated with fingolimod and ocrelizumab.

Read the full article here

Related Articles